var data={"title":"Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/contributors\" class=\"contributor contributor_credentials\">Andr&eacute; Lacroix, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/contributors\" class=\"contributor contributor_credentials\">Lynnette K Nieman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/contributors\" class=\"contributor contributor_credentials\">Kathryn A Martin, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 21, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several compounds inhibit adrenal steroidogenesis by interfering with one or more of the enzymes in the steroidogenic pathway (<a href=\"image.htm?imageKey=ENDO%2F71558\" class=\"graphic graphic_figure graphicRef71558 \">figure 1</a> and <a href=\"image.htm?imageKey=ENDO%2F56781\" class=\"graphic graphic_figure graphicRef56781 \">figure 2</a>). (See <a href=\"topic.htm?path=adrenal-steroid-biosynthesis\" class=\"medical medical_review\">&quot;Adrenal steroid biosynthesis&quot;</a>.)</p><p>These compounds have been used to study the enzymes involved in steroid synthesis, to evaluate the hypothalamic-pituitary axis (<a href=\"topic.htm?path=metyrapone-drug-information\" class=\"drug drug_general\">metyrapone</a>), and to treat some patients with endogenous excess of cortisol, androgen, or mineralocorticoid secretion.</p><p>Indications for the use of these compounds include rapid control of severe hypercortisolism for any etiology of endogenous Cushing's syndrome, persistent hypercortisolism following pituitary surgery for Cushing's disease, while awaiting the control from radiotherapy for Cushing's disease and control of excess steroid production in adrenocortical carcinoma or ectopic corticotropin (ACTH) syndrome.</p><p>This topic provides an overview of the compounds that inhibit glucocorticoid biosynthesis or action. Their use in the treatment of Cushing's syndrome and adrenocortical carcinoma is reviewed in greater detail separately. (See <a href=\"topic.htm?path=medical-therapy-of-hypercortisolism-cushings-syndrome\" class=\"medical medical_review\">&quot;Medical therapy of hypercortisolism (Cushing's syndrome)&quot;</a> and <a href=\"topic.htm?path=treatment-of-adrenocortical-carcinoma#H4\" class=\"medical medical_review\">&quot;Treatment of adrenocortical carcinoma&quot;, section on 'Adjuvant mitotane'</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">ADRENAL ENZYME INHIBITORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">Ketoconazole</a>, <a href=\"topic.htm?path=metyrapone-drug-information\" class=\"drug drug_general\">metyrapone</a>, <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a>, and <a href=\"topic.htm?path=mitotane-drug-information\" class=\"drug drug_general\">mitotane</a> block one or more of the enzymes in the cortisol and other steroid synthetic pathway. The subsequent decrease in cortisol secretion results in a compensatory rise in corticotropin (ACTH) release for most of these compounds. This tends to override the drug-induced cortisol blockade but can also result in accumulation of precursor steroids. These drugs usually do not cause adrenal insufficiency in patients with normal hypothalamic-pituitary-adrenal function [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/1\" class=\"abstract_t\">1</a>] but can do so in those with limited pituitary or adrenal reserve. (See <a href=\"topic.htm?path=medical-therapy-of-hypercortisolism-cushings-syndrome#H19\" class=\"medical medical_review\">&quot;Medical therapy of hypercortisolism (Cushing's syndrome)&quot;, section on 'Oral drugs'</a>.)</p><p>Aminoglutethimide, another drug with antisteroidogenic activity, is no longer available in any world market and will not be discussed further.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Ketoconazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several azole-derived antifungal drugs have antisteroidogenic actions in humans, including <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> and <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>. Ketoconazole is the one most used clinically for the treatment of hypercortisolism. (See <a href=\"topic.htm?path=medical-therapy-of-hypercortisolism-cushings-syndrome#H16432801\" class=\"medical medical_review\">&quot;Medical therapy of hypercortisolism (Cushing's syndrome)&quot;, section on 'Ketoconazole'</a>.)</p><p>These compounds were developed because they inhibit a fungal CYP enzyme system. <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">Ketoconazole</a> has effects on both androgen and cortisol synthesis.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The endocrine effect first described with <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> use was a decrease in androstenedione and testosterone production (due to potent inhibition of C17-20 desmolase), resulting in symptoms of androgen deficiency and gynecomastia [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/2-4\" class=\"abstract_t\">2-4</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The effects of <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> on cortisol synthesis result from its inhibition of CYP11A1 (side-chain cleavage) and of CYP11B1 (conversion of 11-deoxycortisol to cortisol) [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/4,5\" class=\"abstract_t\">4,5</a>]. In many countries, it is the most commonly used enzyme inhibitor for treating patients with Cushing's syndrome. (See <a href=\"topic.htm?path=medical-therapy-of-hypercortisolism-cushings-syndrome#H16432801\" class=\"medical medical_review\">&quot;Medical therapy of hypercortisolism (Cushing's syndrome)&quot;, section on 'Ketoconazole'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">Ketoconazole</a> requires an acid stomach for maximal absorption, which can be decreased by antacids and H2-antagonists [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/4\" class=\"abstract_t\">4</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The side effects of <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> are either due to inhibition of cortisol production (headache, sedation, fatigue, decreased appetite, nausea, and vomiting), or testosterone production (gynecomastia, decreased libido, and impotence). The latter adverse effects make this drug less useful for long-term treatment in male patients. Ketoconazole is also a rare cause of reversible hepatotoxicity [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/6,7\" class=\"abstract_t\">6,7</a>]. In 2013, the US Food and Drug Administration (FDA) issued a warning about the risk of potentially fatal liver toxicity; cases have occurred in patients with no pre-existing hepatic disease or serious underlying medical condition [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/8\" class=\"abstract_t\">8</a>]. This led to its temporary withdrawal from European countries, but the drug is now widely available again [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/9\" class=\"abstract_t\">9</a>]. The clinical use, hepatotoxicity, and monitoring of ketoconazole are reviewed in detail separately. (See <a href=\"topic.htm?path=medical-therapy-of-hypercortisolism-cushings-syndrome#H16432801\" class=\"medical medical_review\">&quot;Medical therapy of hypercortisolism (Cushing's syndrome)&quot;, section on 'Ketoconazole'</a> and <a href=\"topic.htm?path=medical-therapy-of-hypercortisolism-cushings-syndrome#H528456244\" class=\"medical medical_review\">&quot;Medical therapy of hypercortisolism (Cushing's syndrome)&quot;, section on 'Suggested approach'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">Ketoconazole</a> inhibits CYP3A4 strongly and also CYP1A2<em> </em>and CYP2C9, and it has several important drug interactions. Fatal arrhythmias have been reported when ketoconazole has been used in combination with cisapride, and it also increases <a href=\"topic.htm?path=domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">domperidone</a> plasma levels with potential risk to increase QT interval. Several drugs can be potentiated, including <a href=\"topic.htm?path=felodipine-drug-information\" class=\"drug drug_general\">felodipine</a>, <a href=\"topic.htm?path=nifedipine-drug-information\" class=\"drug drug_general\">nifedipine</a>, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>, <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a>, <a href=\"topic.htm?path=simvastatin-drug-information\" class=\"drug drug_general\">simvastatin</a>, and other statins. It can reduce concentrations of aminoglycosides and <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>. If used in the context of adrenal carcinoma, ketoconazole can increase toxicity of <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a>, <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">etoposide</a>, taxanes, and vinca alkaloids.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">Ketoconazole</a> is teratogenic and toxic to animal embryos but has been used without harm to the fetus in the late stages of pregnancy. However, ketoconazole is not the treatment of choice during pregnancy. (See <a href=\"topic.htm?path=cushings-syndrome-in-pregnancy#H5\" class=\"medical medical_review\">&quot;Cushing's syndrome in pregnancy&quot;, section on 'Management'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oral or intravenous <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> can also decrease excess cortisol production, but there is very limited experience with this drug for the treatment of hypercortisolism [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/10-12\" class=\"abstract_t\">10-12</a>].</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Metyrapone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=metyrapone-drug-information\" class=\"drug drug_general\">Metyrapone</a> is used for diagnostic testing of hypothalamic-pituitary-adrenal function, but it can also be given to control hypercortisolism in patients with Cushing's syndrome either of ACTH-independent or ACTH-dependent etiologies. (See <a href=\"topic.htm?path=metyrapone-stimulation-tests\" class=\"medical medical_review\">&quot;Metyrapone stimulation tests&quot;</a> and <a href=\"topic.htm?path=medical-therapy-of-hypercortisolism-cushings-syndrome#H16432822\" class=\"medical medical_review\">&quot;Medical therapy of hypercortisolism (Cushing's syndrome)&quot;, section on 'Metyrapone'</a>.)</p><p><a href=\"topic.htm?path=metyrapone-drug-information\" class=\"drug drug_general\">Metyrapone</a> is mainly an inhibitor of CYP11B1 (11-beta-hydroxylase), which catalyzes the final step in cortisol biosynthesis, conversion of 11-deoxycortisol to cortisol (<a href=\"image.htm?imageKey=ENDO%2F56413\" class=\"graphic graphic_figure graphicRef56413 \">figure 3</a>) [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/1\" class=\"abstract_t\">1</a>]. It also inhibits aldosterone secretion, presumably by inhibition of CYP11B2 (aldosterone synthase), but its effect on levels of potassium and sodium in blood and urine is mitigated by increased production of 11-deoxycorticosterone, which has mineralocorticoid activity; this can worsen salt retention and hypertension [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/13\" class=\"abstract_t\">13</a>]. Pituitary ACTH secretion increases in response to the reduction in cortisol levels; as a result, production of adrenal androgen precursors is also increased. If used long term for management of hypercortisolism, metyrapone may result in acne <span class=\"nowrap\">and/or</span> hirsutism in female patients [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/14-16\" class=\"abstract_t\">14-16</a>]. In the largest retrospective, multicenter series, 195 patients with Cushing's syndrome were treated with metyrapone (as monotherapy in 84 percent) [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/17\" class=\"abstract_t\">17</a>]. The drug was generally well tolerated, and the previously reported potential side effects of hypokalemia, hypertension, and hirsutism were very seldom found; gastrointestinal upset (23 percent) and hypoadrenalism (7 percent) were the most frequent side effects.</p><p>Genetic polymorphisms in steroidogenic enzymes have been implicated in interindividual variations in the responsiveness to <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a>, <a href=\"topic.htm?path=metyrapone-drug-information\" class=\"drug drug_general\">metyrapone</a>, or their combination [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/18\" class=\"abstract_t\">18</a>].</p><p><a href=\"topic.htm?path=metyrapone-drug-information\" class=\"drug drug_general\">Metyrapone</a> has been used in a small number of pregnant women with Cushing's syndrome without significant maternal or perinatal complications [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/19,20\" class=\"abstract_t\">19,20</a>]. Given these limited data, the efficacy and safety of metyrapone in this setting remain unclear. (See <a href=\"topic.htm?path=cushings-syndrome-in-pregnancy#H5\" class=\"medical medical_review\">&quot;Cushing's syndrome in pregnancy&quot;, section on 'Management'</a>.)</p><p><a href=\"topic.htm?path=metyrapone-drug-information\" class=\"drug drug_general\">Metyrapone</a> is widely used in certain countries such as the United Kingdom, but in North America, it is currently available via its new distributor, HRA Pharma, Paris, France (via its speciality pharmacy Direct Success Inc. with an order form available at <a href=\"http://www.hra-pharma.com/&amp;token=RKk7+Eb7ogxZ2E4w56iOhNZ/lvTsn0smo0koacsUGShSVv/N12flncyQEFdlYieH&amp;TOPIC_ID=128\" target=\"_blank\" class=\"external\">www.hra-pharma.com</a> or by phone at 1-855-674-7663).</p><p>A pilot study with the investigational 11-beta-hydroxylase inhibitor osilodrostat (LCI699) showed encouraging efficacy in short-term therapy of Cushing's disease patients [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/21\" class=\"abstract_t\">21</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Etomidate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">Etomidate</a>, another imidazole derivative, is a parenterally administered drug that is given to sedate patients on mechanical ventilators in intensive care units [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/22\" class=\"abstract_t\">22</a>]. Like <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a>, its major adrenal action is to inhibit CYP11B1, but higher doses also inhibit CYP11A1 [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/23-25\" class=\"abstract_t\">23-25</a>]. The net effect is inhibition of adrenocortical function [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/26-29\" class=\"abstract_t\">26-29</a>].</p><p>It may be useful in critically ill patients with Cushing's syndrome or in those who cannot take oral medications. <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">Etomidate</a> is infused intravenously initially with a low, nonhypnotic dose of 0.04 to 0.05 <span class=\"nowrap\">mg/kg</span> per hour (approximately 2.5 to 3 <span class=\"nowrap\">mg/hour),</span> with dose titration based upon serum cortisol (up to 0.1 to 0.3 <span class=\"nowrap\">mg/kg/hour)</span>. This dose lowers serum cortisol concentrations to the normal range (ie, 10 <span class=\"nowrap\">mcg/dL</span> [28 <span class=\"nowrap\">nmol/L])</span> within approximately 10 hours [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/30\" class=\"abstract_t\">30</a>]. The main side effect is fatigue. Monitoring in an intensive care unit is suggested when using etomidate. (See <a href=\"topic.htm?path=medical-therapy-of-hypercortisolism-cushings-syndrome#H21\" class=\"medical medical_review\">&quot;Medical therapy of hypercortisolism (Cushing's syndrome)&quot;, section on 'Intravenous etomidate'</a>.)</p><p class=\"headingAnchor\" id=\"H366108018\"><span class=\"h1\">ADRENOLYTIC AGENTS</span></p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Mitotane</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=mitotane-drug-information\" class=\"drug drug_general\">Mitotane</a> inhibits steroidogenesis but also has adrenolytic activity with longer-term use. It acts on adrenocortical cell mitochondria to inhibit CYP11B1 (11-beta-hydroxylase) and cholesterol side-chain cleavage (CYP11A1) enzymes. It is metabolized into an acyl chloride that binds to important macromolecules in the mitochondria, causing mitochondrial destruction and necrosis of adrenocortical cells [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/31,32\" class=\"abstract_t\">31,32</a>].</p><p>The administration of <a href=\"topic.htm?path=mitotane-drug-information\" class=\"drug drug_general\">mitotane</a> has a cytotoxic effect on adrenal tissue in humans in both normal adrenals and in adrenocortical tumors. Mitotane can produce a &quot;medical&quot; adrenalectomy in patients with Cushing's disease, sometimes in association with pituitary radiotherapy [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/33\" class=\"abstract_t\">33</a>]. It is used most widely in patients with adrenal carcinoma (see <a href=\"topic.htm?path=treatment-of-adrenocortical-carcinoma\" class=\"medical medical_review\">&quot;Treatment of adrenocortical carcinoma&quot;</a>). It is also sometimes used in patients with ectopic corticotropin (ACTH) or corticotropin-releasing hormone (CRH) syndromes alone or in conjunction with one or more adrenal enzyme inhibitors to reduce cortisol synthesis [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/34\" class=\"abstract_t\">34</a>]. (See <a href=\"topic.htm?path=overview-of-the-treatment-of-cushings-syndrome\" class=\"medical medical_review\">&quot;Overview of the treatment of Cushing's syndrome&quot;</a>.)</p><p><a href=\"topic.htm?path=mitotane-drug-information\" class=\"drug drug_general\">Mitotane</a> has several extra-adrenal actions:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It alters the metabolism of cortisol [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/35,36\" class=\"abstract_t\">35,36</a>]. Cortisol is normally metabolized to compounds measurable in urine as 17-hydroxycorticosteroids (17-OHCS) (see <a href=\"topic.htm?path=measurement-of-urinary-excretion-of-endogenous-and-exogenous-glucocorticoids\" class=\"medical medical_review\">&quot;Measurement of urinary excretion of endogenous and exogenous glucocorticoids&quot;</a>).&nbsp;<a href=\"topic.htm?path=mitotane-drug-information\" class=\"drug drug_general\">Mitotane</a> decreases the production of these metabolites by 50 to 80 percent; the excess cortisol is metabolized to 6-beta-hydroxycortisol, a more polar compound that is not measured in the 17-OHCS assay. This is important clinically because the efficacy of mitotane therapy should be assessed by measuring 24-hour urinary free cortisol excretion, not urinary 17-OHCS excretion, which is artifactually low with mitotane.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It may cause new onset or worsening of hypercholesterolemia in patients receiving <a href=\"topic.htm?path=mitotane-drug-information\" class=\"drug drug_general\">mitotane</a> for long periods, perhaps because of inhibition of cholesterol oxidase [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/37\" class=\"abstract_t\">37</a>]. Serum cholesterol concentrations may rise to as high as 560 <span class=\"nowrap\">mg/dL</span> (14.5 <span class=\"nowrap\">mmol/L)</span> after three or more months of therapy. Mitotane treatment should not be terminated in patients in whom it is effective, as therapy with 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibitors (statins) can decrease the high low-density lipoprotein (LDL) cholesterol levels.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It does not interfere with the excretion or assay of urinary cortisol and, therefore, urinary free cortisol measurements using structurally based assay of gas <span class=\"nowrap\">chromatography/mass</span> spectrometry <span class=\"nowrap\">(GS/MS)</span> in mitotane-treated patients accurately reflect integrated plasma free cortisol concentrations as they do in normal subjects; because <a href=\"topic.htm?path=mitotane-drug-information\" class=\"drug drug_general\">mitotane</a> modifies cortisol metabolism, large elevations of 6-hydroxycortisol metabolites in particular can falsely increase urinary free cortisol when measured by immunoassays [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/36\" class=\"abstract_t\">36</a>]. (See <a href=\"topic.htm?path=measurement-of-urinary-excretion-of-endogenous-and-exogenous-glucocorticoids\" class=\"medical medical_review\">&quot;Measurement of urinary excretion of endogenous and exogenous glucocorticoids&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It accelerates the metabolism of halogenated synthetic glucocorticoids, such as <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> and <a href=\"topic.htm?path=fludrocortisone-drug-information\" class=\"drug drug_general\">fludrocortisone</a>, but has less effect on <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> metabolism. <a href=\"topic.htm?path=mitotane-drug-information\" class=\"drug drug_general\">Mitotane</a> can <strong>increase</strong> the requirement for exogenous glucocorticoid in patients in whom adrenal insufficiency is induced who are given halogenated steroids as replacement therapy [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/36,38\" class=\"abstract_t\">36,38</a>]. Mineralocorticoid replacement is not always required, since the zona glomerulosa is relatively spared, but can become required after longer exposure. Maintenance of normal mineralocorticoid activity is important because it puts the patient at lower risk for developing stress-related adrenal crisis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It increases serum levels of cortisol-binding globulin (CBG) and other hormone-binding globulins as much as two- to threefold; the levels return to normal within one year of discontinuing therapy [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/39\" class=\"abstract_t\">39</a>]. Total serum cortisol levels are elevated because of induction of CBG and should not be used for monitoring of cortisol secretion.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The increase in CBG, and mainly alteration in cortisol and glucocorticoid metabolism, probably explains the need to increase the replacement dose of steroids that bind to CBG such as <a href=\"topic.htm?path=hydrocortisone-drug-information\" class=\"drug drug_general\">hydrocortisone</a>, <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a>, and their precursors, cortisone and <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It may also act on the pituitary by an unknown mechanism to inhibit ACTH secretion [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/40\" class=\"abstract_t\">40</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In addition to its effect on CBG, <a href=\"topic.htm?path=mitotane-drug-information\" class=\"drug drug_general\">mitotane</a> increases serum concentrations of other binding globulins, including sex hormone-binding globulin (SHBG) and thyroid hormone-binding globulin (TBG). There may also be a direct inhibitory effect of mitotane on thyroid-stimulating hormone (TSH) secretion [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/41\" class=\"abstract_t\">41</a>]. Serum concentrations of both free testosterone and free thyroxine (T4) may be decreased. This issue is discussed in more detail separately. (See <a href=\"topic.htm?path=treatment-of-adrenocortical-carcinoma#H23\" class=\"medical medical_review\">&quot;Treatment of adrenocortical carcinoma&quot;, section on 'Medical treatment of hormone excess'</a>.)</p><p/><p><a href=\"topic.htm?path=mitotane-drug-information\" class=\"drug drug_general\">Mitotane</a> destroys normal as well as neoplastic adrenal tissue; prolonged administration can result in primary adrenal insufficiency. Urinary free cortisol levels must be monitored and glucocorticoid replacement therapy instituted when appropriate. (See <a href=\"topic.htm?path=treatment-of-adrenocortical-carcinoma\" class=\"medical medical_review\">&quot;Treatment of adrenocortical carcinoma&quot;</a>.)</p><p><a href=\"topic.htm?path=mitotane-drug-information\" class=\"drug drug_general\">Mitotane</a> should <strong>not</strong> be given to pregnant women with Cushing's syndrome, because permanent fetal adrenal damage may ensue [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/42\" class=\"abstract_t\">42</a>]. Women of reproductive age should be on some form of reliable contraception while receiving mitotane.</p><p><a href=\"topic.htm?path=mitotane-drug-information\" class=\"drug drug_general\">Mitotane</a> is taken up by fatty tissues and persists in plasma long after the drug is discontinued [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/43\" class=\"abstract_t\">43</a>]. As a result, the dose of glucocorticoid may have to be tapered to the usual replacement dose over a period of several weeks to months after the patient is cured and mitotane is discontinued.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Dose</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A review of dosing, efficacy, and side effects of <a href=\"topic.htm?path=mitotane-drug-information\" class=\"drug drug_general\">mitotane</a> is found separately. Data on the use of mitotane in patients with adrenal carcinoma are also reviewed separately. (See <a href=\"topic.htm?path=medical-therapy-of-hypercortisolism-cushings-syndrome#H6330785\" class=\"medical medical_review\">&quot;Medical therapy of hypercortisolism (Cushing's syndrome)&quot;, section on 'Mitotane'</a> and <a href=\"topic.htm?path=treatment-of-adrenocortical-carcinoma#H4\" class=\"medical medical_review\">&quot;Treatment of adrenocortical carcinoma&quot;, section on 'Adjuvant mitotane'</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">BLOCKADE OF CORTISOL ACTION</span></p><p class=\"headingAnchor\" id=\"H366107979\"><span class=\"h2\">Mifepristone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">Mifepristone</a> (RU-486) does not inhibit steroidogenesis but instead antagonizes the peripheral actions of glucocorticoids and progestogens [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/44,45\" class=\"abstract_t\">44,45</a>]. It does so because it is a glucocorticoid and progesterone receptor antagonist.</p><p>The major use of <a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">mifepristone</a> is to terminate pregnancy, but it has, on occasion, been given to patients with Cushing's syndrome, particularly with Cushing's disease [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/46,47\" class=\"abstract_t\">46,47</a>], ectopic corticotropin (ACTH) syndrome, or adrenal carcinoma [<a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/48,49\" class=\"abstract_t\">48,49</a>]. It also blocks the action of exogenous glucocorticoids, making it difficult to assess and treat the systemic peripheral glucocorticoid deficiency that it may induce.</p><p>The clinical use of <a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">mifepristone</a> for hypercortisolism is reviewed separately. (See <a href=\"topic.htm?path=medical-therapy-of-hypercortisolism-cushings-syndrome#H6330490\" class=\"medical medical_review\">&quot;Medical therapy of hypercortisolism (Cushing's syndrome)&quot;, section on 'Glucocorticoid-receptor antagonists (mifepristone)'</a>.)</p><p class=\"headingAnchor\" id=\"H306069384\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Several compounds inhibit adrenal steroidogenesis by interfering with one or more of the enzymes in the steroidogenic pathway (<a href=\"image.htm?imageKey=ENDO%2F71558\" class=\"graphic graphic_figure graphicRef71558 \">figure 1</a> and <a href=\"image.htm?imageKey=ENDO%2F56781\" class=\"graphic graphic_figure graphicRef56781 \">figure 2</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Indications for the use of these compounds include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Rapid control of severe hypercortisolism for any etiology of endogenous Cushing's syndrome</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Persistent hypercortisolism following pituitary surgery for Cushing's disease</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>While awaiting the control from radiotherapy for Cushing's disease</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Control of excess steroid production in adrenocortical carcinoma or ectopic corticotropin (ACTH) syndrome</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Second-line hormonal therapy for prostate cancer (<a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a>) (see <a href=\"topic.htm?path=alternative-endocrine-therapies-for-castration-resistant-prostate-cancer#H15\" class=\"medical medical_review\">&quot;Alternative endocrine therapies for castration-resistant prostate cancer&quot;, section on 'Ketoconazole'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">Ketoconazole</a>, <a href=\"topic.htm?path=metyrapone-drug-information\" class=\"drug drug_general\">metyrapone</a>, and <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a> block one or more of the enzymes in the cortisol and other steroid synthetic pathway. The subsequent decrease in cortisol secretion results in a compensatory rise in ACTH release for most of these compounds. This tends to override the drug-induced steroidogenic blockade. As a result, these drugs usually do not cause adrenal insufficiency in patients with normal hypothalamic-pituitary-adrenal function but can do so in those with limited pituitary or adrenal reserve. (See <a href=\"#H2\" class=\"local\">'Adrenal enzyme inhibitors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=mitotane-drug-information\" class=\"drug drug_general\">Mitotane</a> inhibits steroidogenesis but also has adrenolytic activity with longer-term use. It is used most commonly for adrenal carcinoma but is sometimes used for Cushing's syndrome. (See <a href=\"#H7\" class=\"local\">'Mitotane'</a> above and <a href=\"topic.htm?path=medical-therapy-of-hypercortisolism-cushings-syndrome#H6330785\" class=\"medical medical_review\">&quot;Medical therapy of hypercortisolism (Cushing's syndrome)&quot;, section on 'Mitotane'</a> and <a href=\"topic.htm?path=treatment-of-adrenocortical-carcinoma#H4\" class=\"medical medical_review\">&quot;Treatment of adrenocortical carcinoma&quot;, section on 'Adjuvant mitotane'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The major use of <a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">mifepristone</a> is to terminate pregnancy, but it has, on occasion, been given to patients with Cushing's syndrome, particularly with Cushing's disease, ectopic ACTH syndrome, or adrenal carcinoma. (See <a href=\"#H366107979\" class=\"local\">'Mifepristone'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/1\" class=\"nounderline abstract_t\">LIDDLE GW, ISLAND D, LANCE EM, HARRIS AP. Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 beta-hydroxylation. J Clin Endocrinol Metab 1958; 18:906.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/2\" class=\"nounderline abstract_t\">Pont A, Williams PL, Azhar S, et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982; 142:2137.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/3\" class=\"nounderline abstract_t\">DeFelice R, Johnson DG, Galgiani JN. Gynecomastia with ketoconazole. Antimicrob Agents Chemother 1981; 19:1073.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/4\" class=\"nounderline abstract_t\">Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987; 317:812.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/5\" class=\"nounderline abstract_t\">Loose DS, Kan PB, Hirst MA, et al. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 1983; 71:1495.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/6\" class=\"nounderline abstract_t\">McCance DR, Hadden DR, Kennedy L, et al. Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1987; 27:593.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/7\" class=\"nounderline abstract_t\">Castinetti F, Guignat L, Giraud P, et al. Ketoconazole in Cushing's disease: is it worth a try? J Clin Endocrinol Metab 2014; 99:1623.</a></li><li class=\"breakAll\">FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. US FDA Drug Safety Communication. Last updated October 21, 2013. Food and Drug Administration. (Available online at www.fda.gov/Drugs/DrugSafety/ucm362415.htm (accessed September 28, 2015)).</li><li class=\"breakAll\">Recommendation for maintenance of orphan designation at the time of marketing authorization: Ketoconazole HRA (ketoconazole) for the treatment of Cushing&rsquo;s syndrome. European Medicines Agency/Committee for Orphan Medicinal Products orphan designation recommendation. Last updated January 30, 2015. European Medicines Agency. (Available online at www.ema.europa.eu/docs/en_GB/document_library/Orphan_review/2015/01/WC500181644.pdf (accessed September 28, 2015)).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/10\" class=\"nounderline abstract_t\">Riedl M, Maier C, Zettinig G, et al. Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol 2006; 154:519.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/11\" class=\"nounderline abstract_t\">van der Pas R, Hofland LJ, Hofland J, et al. Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J Endocrinol 2012; 215:403.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/12\" class=\"nounderline abstract_t\">Schwetz V, Aberer F, Stiegler C, et al. Fluconazole and acetazolamide in the treatment of ectopic Cushing's syndrome with severe metabolic alkalosis. Endocrinol Diabetes Metab Case Rep 2015; 2015:150027.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/13\" class=\"nounderline abstract_t\">COPPAGE WS Jr, ISLAND D, SMITH M, LIDDLE GW. Inhibition of aldosterone secretion and modification of electrolyte excretion in man by a chemical inhibitor of 11 beta-hydroxylation. J Clin Invest 1959; 38:2101.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/14\" class=\"nounderline abstract_t\">Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1991; 35:169.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/15\" class=\"nounderline abstract_t\">Schteingart DE. Drugs in the medical treatment of Cushing's syndrome. Expert Opin Emerg Drugs 2009; 14:661.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/16\" class=\"nounderline abstract_t\">Feelders RA, Hofland LJ, de Herder WW. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology 2010; 92 Suppl 1:111.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/17\" class=\"nounderline abstract_t\">Daniel E, Aylwin S, Mustafa O, et al. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. J Clin Endocrinol Metab 2015; 100:4146.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/18\" class=\"nounderline abstract_t\">Valassi E, Aulinas A, Glad CA, et al. A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome. Clin Endocrinol (Oxf) 2017; 87:433.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/19\" class=\"nounderline abstract_t\">Aron DC, Schnall AM, Sheeler LR. Cushing's syndrome and pregnancy. Am J Obstet Gynecol 1990; 162:244.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/20\" class=\"nounderline abstract_t\">Buescher MA, McClamrock HD, Adashi EY. Cushing syndrome in pregnancy. Obstet Gynecol 1992; 79:130.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/21\" class=\"nounderline abstract_t\">Bertagna X, Pivonello R, Fleseriu M, et al. LCI699, a potent 11&beta;-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab 2014; 99:1375.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/22\" class=\"nounderline abstract_t\">Forman SA. Clinical and molecular pharmacology of etomidate. Anesthesiology 2011; 114:695.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/23\" class=\"nounderline abstract_t\">Wagner RL, White PF, Kan PB, et al. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984; 310:1415.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/24\" class=\"nounderline abstract_t\">Fry DE, Griffiths H. The inhibition by etomidate of the 11 beta-hydroxylation of cortisol. Clin Endocrinol (Oxf) 1984; 20:625.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/25\" class=\"nounderline abstract_t\">de Jong FH, Mallios C, Jansen C, et al. Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab 1984; 59:1143.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/26\" class=\"nounderline abstract_t\">Wagner RL, White PF. Etomidate inhibits adrenocortical function in surgical patients. Anesthesiology 1984; 61:647.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/27\" class=\"nounderline abstract_t\">Fraser R, Watt I, Gray CE, et al. The effect of etomidate on adrenocortical function in dogs before and during hemorrhagic shock. Endocrinology 1984; 115:2266.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/28\" class=\"nounderline abstract_t\">Fellows IW, Bastow MD, Byrne AJ, Allison SP. Adrenocortical suppression in multiply injured patients: a complication of etomidate treatment. Br Med J (Clin Res Ed) 1983; 287:1835.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/29\" class=\"nounderline abstract_t\">Preda VA, Sen J, Karavitaki N, Grossman AB. Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. Eur J Endocrinol 2012; 167:137.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/30\" class=\"nounderline abstract_t\">Schulte HM, Benker G, Reinwein D, et al. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990; 70:1426.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/31\" class=\"nounderline abstract_t\">NELSON AA, WOODARD G. Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE). Arch Pathol (Chic) 1949; 48:387.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/32\" class=\"nounderline abstract_t\">CUETO C, BROWN JH, RICHARDSON AP Jr. Biological studies on an adrenocorticolytic agent and the isolation of the active components. Endocrinology 1958; 62:334.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/33\" class=\"nounderline abstract_t\">Baudry C, Coste J, Bou Khalil R, et al. Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. Eur J Endocrinol 2012; 167:473.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/34\" class=\"nounderline abstract_t\">Kamenick&yacute; P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2011; 96:2796.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/35\" class=\"nounderline abstract_t\">BLEDSOE T, ISLAND DP, NEY RL, LIDDLE GW. AN EFFECT OF O,P'-DDD ON THE EXTRA-ADRENAL METABOLISM OF CORTISOL IN MAN. J Clin Endocrinol Metab 1964; 24:1303.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/36\" class=\"nounderline abstract_t\">Chortis V, Taylor AE, Schneider P, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5&alpha;-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 2013; 98:161.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/37\" class=\"nounderline abstract_t\">Yeung SC, Chiu AC, Vassilopoulou-Sellin R, Gagel RF. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev 1998; 19:144.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/38\" class=\"nounderline abstract_t\">Robinson BG, Hales IB, Henniker AJ, et al. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol (Oxf) 1987; 27:437.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/39\" class=\"nounderline abstract_t\">van Seters AP, Moolenaar AJ. Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol (Copenh) 1991; 124:526.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/40\" class=\"nounderline abstract_t\">Takamatsu J, Kitazawa A, Nakata K, et al. Does mitotane reduce endogenous ACTH secretion? N Engl J Med 1981; 305:957.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/41\" class=\"nounderline abstract_t\">Zatelli MC, Gentilin E, Daffara F, et al. Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology 2010; 151:2453.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/42\" class=\"nounderline abstract_t\">Leiba S, Weinstein R, Shindel B, et al. The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Ann Endocrinol (Paris) 1989; 50:49.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/43\" class=\"nounderline abstract_t\">Hogan TF, Citrin DL, Johnson BM, et al. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Cancer 1978; 42:2177.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/44\" class=\"nounderline abstract_t\">Gaillard RC, Poffet D, Riondel AM, Saurat JH. RU 486 inhibits peripheral effects of glucocorticoids in humans. J Clin Endocrinol Metab 1985; 61:1009.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/45\" class=\"nounderline abstract_t\">Bertagna X, Basin C, Picard F, et al. Peripheral antiglucocorticoid action of RU 486 in man. Clin Endocrinol (Oxf) 1988; 28:537.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/46\" class=\"nounderline abstract_t\">Bertagna X, Bertagna C, Laudat MH, et al. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab 1986; 63:639.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/47\" class=\"nounderline abstract_t\">Fleseriu M, Biller BM, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97:2039.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/48\" class=\"nounderline abstract_t\">Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 2009; 160:1003.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-and-toxicity-of-adrenal-enzyme-inhibitors-and-adrenolytic-agents/abstract/49\" class=\"nounderline abstract_t\">Bilgin YM, van der Wiel HE, Fischer HR, De Herder WW. Treatment of severe psychosis due to ectopic Cushing's syndrome. J Endocrinol Invest 2007; 30:776.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 128 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H306069384\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">ADRENAL ENZYME INHIBITORS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Ketoconazole</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Metyrapone</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Etomidate</a></li></ul></li><li><a href=\"#H366108018\" id=\"outline-link-H366108018\">ADRENOLYTIC AGENTS</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Mitotane</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">- Dose</a></li></ul></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">BLOCKADE OF CORTISOL ACTION</a><ul><li><a href=\"#H366107979\" id=\"outline-link-H366107979\">Mifepristone</a></li></ul></li><li><a href=\"#H306069384\" id=\"outline-link-H306069384\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ENDO/128|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/71558\" class=\"graphic graphic_figure\">- Normal adrenal steroidogenesis</a></li><li><a href=\"image.htm?imageKey=ENDO/56781\" class=\"graphic graphic_figure\">- Adrenal steroid inhibitors</a></li><li><a href=\"image.htm?imageKey=ENDO/56413\" class=\"graphic graphic_figure\">- Action of metyrapone</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adrenal-steroid-biosynthesis\" class=\"medical medical_review\">Adrenal steroid biosynthesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=alternative-endocrine-therapies-for-castration-resistant-prostate-cancer\" class=\"medical medical_review\">Alternative endocrine therapies for castration-resistant prostate cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cushings-syndrome-in-pregnancy\" class=\"medical medical_review\">Cushing's syndrome in pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=measurement-of-urinary-excretion-of-endogenous-and-exogenous-glucocorticoids\" class=\"medical medical_review\">Measurement of urinary excretion of endogenous and exogenous glucocorticoids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medical-therapy-of-hypercortisolism-cushings-syndrome\" class=\"medical medical_review\">Medical therapy of hypercortisolism (Cushing's syndrome)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=metyrapone-stimulation-tests\" class=\"medical medical_review\">Metyrapone stimulation tests</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-treatment-of-cushings-syndrome\" class=\"medical medical_review\">Overview of the treatment of Cushing's syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-adrenocortical-carcinoma\" class=\"medical medical_review\">Treatment of adrenocortical carcinoma</a></li></ul></div></div>","javascript":null}